InsiderDB
Sign inStart free trial

Rep. Robert P. Bresnahan, Jr. sold Incyte (INCY)

Rep. Robert P. Bresnahan, Jr. (R-PA-8) · $1K–$15K · traded May 15, 2025

Transaction
Sold
Amount
$1K–$15K
Owner
Not stated
Traded
May 15, 2025
Disclosed
May 31, 2025
Days to disclose
16
Asset type
Stock
As filed
Incyte Corporation - Common Stock
Industry
Biotechnology · Healthcare
Official filing ↗All of Bresnahan's tradesAll Congress trades in INCY

Other trades in this filing

All of Bresnahan's trades →

Recent Congress trades in INCY

Company context for INCY

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. INCYFinancial report·SEC EDGAR

    INCY: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 4:03 PM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. INCYCompany announcement·SEC EDGAR

    INCY: Financial results

    Filed 8-K for an event or period dated 2026-10-29. Financial results.

    Public: Oct 29, 2026, 7:03 AM EDTEvent / period: Oct 29, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. INCYRegulatory notice·Federal Register

    Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ATEBRIOZ (Zilurgisertib)

    The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ATEBRIOZ (zilurgisertib), approved September 25, 2026, manufactured by Incyte Corporation meets the criteria for a priority review voucher.

    Public: Oct 28, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.